BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research Summit

Rhea-AI Summary

BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced that Dr. Ralph Kern will present a corporate overview at the 12th Annual California ALS Research Summit on January 27, 2022, at 4:45 p.m. ET. The summit, held virtually on January 27-28, focuses on advancing research in neurodegenerative diseases. BrainStorm's NurOwn^® technology, which utilizes autologous MSC-NTF cells, aims to treat conditions like ALS and has received Orphan Drug designation from the FDA and EMA. For more details and registration, visit the official summit page.

NEW YORK, Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D., MHSc, President and Chief Medical Officer of BrainStorm Cell Therapeutics, will provide a corporate and clinical overview at the 12^th Annual California ALS Research Summit, which is being held virtually January 27-28, 2022.

Dr. Kern's presentation will take place on January 27, 2022, at 4:45 p.m. ET. Those interested in registering for the summit can do so here.         

About NurOwn®

The NurOwn^® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions. NurOwn (autologous MSC-NTF cells) is designed to effectively deliver high levels of multiple neurotrophic factors (NTFs) and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn^® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989) and a grant from I AM ALS and the ALS Association. BrainStorm completed a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS) and was supported by a grant from the National MS Society (NMSS).

For more information, visit the company's website at www.brainstorm-cell.com.

Safe-Harbor Statement 

Statements in this announcement other than historical data and information, including statements regarding future NurOwn^® manufacturing and clinical development plans, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect," "likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, the prospects for regulatory approval of BrainStorm's NurOwn^® treatment candidate, the initiation, completion, and success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn^® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture, or to use third parties to manufacture, and commercialize the NurOwn^® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Contacts:

Brainstorm Contacts

Investor Relations:
John Mullaly
LifeSci Advisors, LLC
Phone: +1 617-429-3548
jmullaly@lifesciadvisors.com 

Media:
Mariesa Kemble
kemblem@mac.com 

Logo: https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-at-the-12th-annual-california-als-research-summit-301469482.html

SOURCE Brainstorm Cell Therapeutics Inc

FAQ

What is the date and time of BrainStorm's presentation at the ALS Research Summit?

BrainStorm's presentation is scheduled for January 27, 2022, at 4:45 p.m. ET.

Where can I register for the 12th Annual California ALS Research Summit?

You can register for the summit through the official webpage linked in the press release.

What is NurOwn® and its significance in treating ALS?

NurOwn® is a technology platform that utilizes autologous MSC-NTF cells for treating neurodegenerative diseases, including ALS.

What designation has NurOwn® received from regulatory agencies?

NurOwn® has received Orphan Drug designation from both the FDA and the EMA.

What trials has BrainStorm completed for its treatments?

BrainStorm has completed a Phase 3 trial in ALS and a Phase 2 trial for progressive multiple sclerosis.